Zobrazeno 1 - 10
of 136
pro vyhledávání: '"Theodore F, Logan"'
Autor:
Michael B. Atkins, Sandra J. Lee, Bartosz Chmielowski, Ahmad A. Tarhini, Gary I. Cohen, Thach-Giao Truong, Helen H. Moon, Diwakar Davar, Mark O'Rourke, Joseph J. Stephenson, Brendan D. Curti, Walter J. Urba, Joanna M. Brell, Pauline Funchain, Kari L. Kendra, Alexandra P. Ikeguchi, Anthony Jaslowski, Charles L. Bane, Mark A. Taylor, Madhuri Bajaj, Robert M. Conry, Robert J. Ellis, Theodore F. Logan, Noel Laudi, Jeffrey A. Sosman, David G. Crockett, Andrew L. Pecora, Ian J. Okazaki, Sowjanya Reganti, Sunandana Chandra, Samantha Guild, Helen X. Chen, Howard Z. Streicher, Jedd D. Wolchok, Antoni Ribas, John M. Kirkwood
Publikováno v:
Journal of Clinical Oncology. 41:186-197
PURPOSE Combination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4–blockade and dual BRAF/MEK inhibition have each shown significant clinical benefit in patients with BRAFV600-mutant metastatic melanoma, leading to broad regulatory a
Autor:
Joseph I. Clark, Jatinder Singh, Marc S. Ernstoff, Christopher D. Lao, Lawrence E. Flaherty, Theodore F. Logan, Brendan Curti, Sanjiv S. Agarwala, Bret Taback, Lee Cranmer, Jose Lutzky, Theresa L. Luna, Sandra Aung, David H. Lawson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-8 (2018)
Abstract Background Preclinical studies suggest that BRAF inhibitors enhance anti-tumor immunity and antigen presentation. Combination BRAF inhibition with immunotherapy is an appealing therapeutic approach. We sequenced vemurafenib with HD IL-2 in p
Externí odkaz:
https://doaj.org/article/5cdc7070ed8046e696ecf169baa8612b
Autor:
Brendan Curti, Gregory A. Daniels, David F. McDermott, Joseph I. Clark, Howard L. Kaufman, Theodore F. Logan, Jatinder Singh, Meenu Kaur, Theresa L. Luna, Nancy Gregory, Michael A. Morse, Michael K. K. Wong, Janice P. Dutcher
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-9 (2017)
Abstract Background Immune related adverse events (irAEs) are associated with immunotherapy for cancer and while results suggest improvement in tumor control and overall survival in those experiencing irAEs, the long-term impact is debated. We evalua
Externí odkaz:
https://doaj.org/article/10b65dd26def43998f2aa87eba83b4f1
Autor:
Susan Halabi, Daniel J. George, Andrew Protheroe, Christopher W. Ryan, Lisa M. Pickering, Igor Puzanov, Theodore F. Logan, Christian K. Kollmannsberger, John D. Hainsworth, Robert E. Hawkins, Joel Picus, Ulka N. Vaishampayan, Jorge A. Garcia, Robert J. Jones, Walter M. Stadler, Tim Eisen, Qian Yang, Andrea Carmack, Andrew B. Nixon, Andrew J. Armstrong
All supplementary data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a4bd2de2e8c56ad547410aae807a181
https://doi.org/10.1158/1078-0432.22478711.v1
https://doi.org/10.1158/1078-0432.22478711.v1
Autor:
Susan Halabi, Daniel J. George, Andrew Protheroe, Christopher W. Ryan, Lisa M. Pickering, Igor Puzanov, Theodore F. Logan, Christian K. Kollmannsberger, John D. Hainsworth, Robert E. Hawkins, Joel Picus, Ulka N. Vaishampayan, Jorge A. Garcia, Robert J. Jones, Walter M. Stadler, Tim Eisen, Qian Yang, Andrea Carmack, Andrew B. Nixon, Andrew J. Armstrong
Supplementary Figure 4A. Kaplan-Meier PFS curves by treatment and dichotomized angiokines groups for following angiokines: TGFb-R3, HGF, TSP-2, OPN, IL-6, SDF-1, Ang-2, ICAM-1, TGF-b2, TIMP-1, BMP-9, PDGF-BB, VCAM-1, PDGF-AA, VEGF-D, TGF-b1, VEGF-R1,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1998b18eaf225cf4f04c065548bb9e46
https://doi.org/10.1158/1078-0432.22478714.v1
https://doi.org/10.1158/1078-0432.22478714.v1
Autor:
Susan Halabi, Daniel J. George, Andrew Protheroe, Christopher W. Ryan, Lisa M. Pickering, Igor Puzanov, Theodore F. Logan, Christian K. Kollmannsberger, John D. Hainsworth, Robert E. Hawkins, Joel Picus, Ulka N. Vaishampayan, Jorge A. Garcia, Robert J. Jones, Walter M. Stadler, Tim Eisen, Qian Yang, Andrea Carmack, Andrew B. Nixon, Andrew J. Armstrong
Supplementary Figure 2. Kaplan-Meier PFS curves by dichotomized angiokines: CD-73, BMP-9, VEGF-R1, PDGF-BB, VEGF, IL-6, VCAM-1, OPN, HGF, PDGF-AA, TGFb-R3, TGF-b1, VEGF-R3, and TGF-b2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ab7f5e5968deb4751491c8cb9067fdb
https://doi.org/10.1158/1078-0432.22478723
https://doi.org/10.1158/1078-0432.22478723
Autor:
Susan Halabi, Daniel J. George, Andrew Protheroe, Christopher W. Ryan, Lisa M. Pickering, Igor Puzanov, Theodore F. Logan, Christian K. Kollmannsberger, John D. Hainsworth, Robert E. Hawkins, Joel Picus, Ulka N. Vaishampayan, Jorge A. Garcia, Robert J. Jones, Walter M. Stadler, Tim Eisen, Qian Yang, Andrea Carmack, Andrew B. Nixon, Andrew J. Armstrong
CONSORT diagram
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4b071406c322c24f4475f84e94a1ba1
https://doi.org/10.1158/1078-0432.22478726
https://doi.org/10.1158/1078-0432.22478726
Autor:
Ronald Levy, Mario Sznol, Holbrook Kohrt, Suba Krishnan, Maria Jure-Kunkel, Jaclyn Neely, Satyendra Suryawanshi, Tara C. Gangadhar, Walter J. Urba, Michele Maio, Paolo A. Ascierto, Vanna Chiarion-Sileni, Caroline Robert, Henrik Schmidt, Omid Hamid, Ignacio Melero, David McDermott, F. Stephen Hodi, Theodore F. Logan, Neil H. Segal
Methods Supplement Supplementary Table 1. Patients Included in E-R Analysis Supplementary Table 2. Patients From Studies -006 and -011 Not Included in ER Analysis Supplementary Fig 1. Serum concentration:time profile of urelumab across the dose range
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65720a4278044c24808c829fe7528a9f
https://doi.org/10.1158/1078-0432.22466547.v1
https://doi.org/10.1158/1078-0432.22466547.v1
Autor:
Susan Halabi, Daniel J. George, Andrew Protheroe, Christopher W. Ryan, Lisa M. Pickering, Igor Puzanov, Theodore F. Logan, Christian K. Kollmannsberger, John D. Hainsworth, Robert E. Hawkins, Joel Picus, Ulka N. Vaishampayan, Jorge A. Garcia, Robert J. Jones, Walter M. Stadler, Tim Eisen, Qian Yang, Andrea Carmack, Andrew B. Nixon, Andrew J. Armstrong
Supplementary Figure 3. Kaplan-Meier OS curves by dichotomized angiokines: VEGF-D, VEGF, VEGF-R1, PDGF-AA, TGF-b1, VEGF-R3, HER-3, BMP-9, CD-73, VEGF-R2, TGF-b2, SDF-1, PDGF-BB, and TGFb-R3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1092d144e84b1ce021a4efc182ba5459
https://doi.org/10.1158/1078-0432.22478720
https://doi.org/10.1158/1078-0432.22478720
Autor:
Ronald Levy, Mario Sznol, Holbrook Kohrt, Suba Krishnan, Maria Jure-Kunkel, Jaclyn Neely, Satyendra Suryawanshi, Tara C. Gangadhar, Walter J. Urba, Michele Maio, Paolo A. Ascierto, Vanna Chiarion-Sileni, Caroline Robert, Henrik Schmidt, Omid Hamid, Ignacio Melero, David McDermott, F. Stephen Hodi, Theodore F. Logan, Neil H. Segal
Purpose: Urelumab is an agonist antibody to CD137 with potential application as an immuno-oncology therapeutic. Data were analyzed to assess safety, tolerability, and pharmacodynamic activity of urelumab, including the dose selected for ongoing devel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2738f0a4f365b0756eb1f8573e82b4ff
https://doi.org/10.1158/1078-0432.c.6526350.v1
https://doi.org/10.1158/1078-0432.c.6526350.v1